Evidence map›Paper›PMID 33467751›Full record

ArticleMolecules (Basel, Switzerland)2021

Targeting S100B with Peptides Encoding Intrinsic Aggregation-Prone Sequence Segments.

Joana S Cristóvão, Mariana A Romão, Rodrigo Gallardo, Joost Schymkowitz, Frederic Rousseau, Cláudio M Gomes

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker.International journal of molecular sciences · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joana S CristóvãoBiosystems and Integrative Sciences Institute, Faculdade de Ciências, Universidade Lisboa, 1749-016 Lisbon, Portugal.
Mariana A RomãoBiosystems and Integrative Sciences Institute, Faculdade de Ciências, Universidade Lisboa, 1749-016 Lisbon, Portugal.
Rodrigo GallardoVIB Switch Laboratory, Flanders Institute for Biotechnology (VIB), 3000 Leuven, Belgium.
Joost SchymkowitzVIB Switch Laboratory, Flanders Institute for Biotechnology (VIB), 3000 Leuven, Belgium.ORCID 0000-0003-2020-0168
Frederic RousseauVIB Switch Laboratory, Flanders Institute for Biotechnology (VIB), 3000 Leuven, Belgium.
Cláudio M GomesBiosystems and Integrative Sciences Institute, Faculdade de Ciências, Universidade Lisboa, 1749-016 Lisbon, Portugal.ORCID 0000-0003-4662-6933
University of Lisbon · PTVlaams Instituut voor Biotechnologie · BE

Funding

Bial Foundation PT/FB/BL-2014-343COST Action TD1304 - the Network for the Biology of Zinc Zinc-Net - Training InternshipFEBS - Federation Biochemical Societies Summer FellowshipFundação para a Ciência e a Tecnologia (Portugal) PTDC/NEU-NMC/2138/2014Fundação para a Ciência e a Tecnologia (Portugal) SFRH/BD/101171/2014Fundação para a Ciência e a Tecnologia (Portugal) SFRH/BD/114390/2016Fundação para a Ciência e a Tecnologia (Portugal) UID/Multi/04046/2013
6 · The paper itself

Abstract

S100 proteins assume a diversity of oligomeric states including large order self-assemblies, with an impact on protein structure and function. Previous work has uncovered that S100 proteins, including S100B, are prone to undergo β-aggregation under destabilizing conditions. This propensity is encoded in aggregation-prone regions (APR) mainly located in segments at the homodimer interface, and which are therefore mostly shielded from the solvent and from deleterious interactions, under native conditions. As in other systems, this characteristic may be used to develop peptides with pharmacological potential that selectively induce the aggregation of S100B through homotypic interactions with its APRs, resulting in functional inhibition through a loss of function. Here we report initial studies towards this goal. We applied the TANGO algorithm to identify specific APR segments in S100B helix IV and used this information to design and synthesize S100B-derived APR peptides. We then combined fluorescence spectroscopy, transmission electron microscopy, biolayer interferometry, and aggregation kinetics and determined that the synthetic peptides have strong aggregation propensity, interact with S100B, and may promote co-aggregation reactions. In this framework, we discuss the considerable potential of such APR-derived peptides to act pharmacologically over S100B in numerous physiological and pathological conditions, for instance as modifiers of the S100B interactome or as promoters of S100B inactivation by selective aggregation.

Indexed as

Amino Acid SequenceHumansModels, MolecularMolecular Targeted TherapyNeoplasmsNeurodegenerative DiseasesPeptidesProtein AggregatesProtein ConformationProtein FoldingS100 Calcium Binding Protein beta SubunitPeptidesProtein AggregatesS100 Calcium Binding Protein beta Subunitamyloidprotein aggregationprotein biophysicsS100 proteinsstructural biology

Identifiers

PMID33467751
PMCPMC7830867
OpenAlexW3121081355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.